

Ying Sun

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/657348/publications.pdf>

Version: 2024-02-01

38
papers

574
citations

623734

14
h-index

677142

22
g-index

46
all docs

46
docs citations

46
times ranked

742
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the SMO oncogene by miR-326 inhibits glioma biological behaviors and stemness. <i>Neuro-Oncology</i> , 2015, 17, 243-253.	1.2	66
2	MMP-9 and IL-6 are potential biomarkers for disease activity in Takayasu's arteritis. <i>International Journal of Cardiology</i> , 2012, 156, 236-238.	1.7	43
3	Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF- β 1/SMADs pathway. <i>Biomedicine and Pharmacotherapy</i> , 2018, 105, 841-847.	5.6	35
4	Cyclophosphamide could be a better choice than methotrexate as induction treatment for patients with more severe Takayasu's arteritis. <i>Rheumatology International</i> , 2017, 37, 2019-2026.	3.0	31
5	Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 117-123.	0.9	31
6	The critical role of IL-6 in the pathogenesis of Takayasu arteritis. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S21-7.	0.8	31
7	Value of contrast-enhanced ultrasonography of the carotid artery for evaluating disease activity in Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2019, 21, 24.	3.5	29
8	Value of whole-body contrast-enhanced magnetic resonance angiography with vessel wall imaging in quantitative assessment of disease activity and follow-up examination in Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2016, 35, 685-693.	2.2	28
9	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. <i>American Journal of Human Genetics</i> , 2021, 108, 84-99.	6.2	26
10	Autophagy promotes aortic adventitial fibrosis via the IL-6/Jak1 signaling pathway in Takayasu's arteritis. <i>Journal of Autoimmunity</i> , 2019, 99, 39-47.	6.5	23
11	Features of urate deposition in patients with gouty arthritis of the foot using dual-energy computed tomography. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 560-567.	1.9	22
12	^{18}F -FDG-PET/CT: an accurate method to assess the activity of Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2018, 37, 1927-1935.	2.2	18
13	Dual-energy computed tomography for monitoring the effect of urate-lowering therapy in gouty arthritis. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 880-885.	1.9	17
14	The effects of dopamine receptor 2 expression on B cells on bone metabolism and TNF- α levels in rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 352.	1.9	15
15	Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232097523.	2.5	14
16	Serum complement 3 is a potential biomarker for assessing disease activity in Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2021, 23, 63.	3.5	14
17	New urate depositions on dual-energy computed tomography in gouty arthritis during urate-lowering therapy. <i>Rheumatology International</i> , 2017, 37, 1365-1372.	3.0	12
18	YKL-40 as a new biomarker of disease activity in Takayasu arteritis. <i>International Journal of Cardiology</i> , 2019, 293, 231-237.	1.7	12

#	ARTICLE	IF	CITATIONS
19	Effectiveness and safety of tocilizumab in patients with refractory or severe Takayasu's arteritis: A prospective cohort study in a Chinese population. <i>Joint Bone Spine</i> , 2021, 88, 105186.	1.6	12
20	Radiology and biomarkers in assessing disease activity in Takayasu arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 53-59.	1.9	11
21	Effectiveness and safety of leflunomide compared with cyclophosphamide as induction therapy in Takayasu's arteritis: an observational study. <i>Therapeutic Advances in Chronic Disease</i> , 2020, 11, 204062232092201.	2.5	10
22	Epidemiology of Takayasu arteritis in Shanghai: A hospital-based study and systematic review. <i>International Journal of Rheumatic Diseases</i> , 2021, 24, 1247-1256.	1.9	10
23	A comprehensive profile of chemokines in the peripheral blood and vascular tissue of patients with Takayasu arteritis. <i>Arthritis Research and Therapy</i> , 2022, 24, 49.	3.5	10
24	The value of interleukin-6 in predicting disease relapse for Takayasu arteritis during 2-year follow-up. <i>Clinical Rheumatology</i> , 2020, 39, 3417-3425.	2.2	9
25	FABP3 overexpression promotes vascular fibrosis in Takayasu's arteritis by enhancing fatty acid oxidation in aorta adventitial fibroblasts. <i>Rheumatology</i> , 2022, 61, 3071-3081.	1.9	9
26	Characteristics and Medium-term Outcomes of Takayasu Arteritis-related Renal Artery Stenosis: Analysis of a Large Chinese Cohort. <i>Journal of Rheumatology</i> , 2021, 48, 87-93.	2.0	8
27	The effect of core fucosylation-mediated regulation of multiple signaling pathways on lung pericyte activation and fibrosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2019, 117, 105639.	2.8	6
28	Serum leptin, a potential predictor of long-term angiographic progression in Takayasu's arteritis. <i>International Journal of Rheumatic Diseases</i> , 2019, 22, 2134-2142.	1.9	5
29	Comparison between photodynamic therapy with topical application of 5-aminolevulinic acid and CO2 laser therapy in the treatment of cervical condylomata acuminata: a randomized controlled trial. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 11342-6.	1.3	4
30	Taurine Transporter dEAAT2 is Required for Auditory Transduction in Drosophila. <i>Neuroscience Bulletin</i> , 2018, 34, 939-950.	2.9	3
31	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 161-170.	0.8	3
32	Effectiveness of benzbromarone versus febuxostat in gouty patients: a retrospective study. <i>Clinical Rheumatology</i> , 2022, 41, 2121-2128.	2.2	3
33	Risk assessment model for heart failure in Chinese patients with Takayasu's arteritis. <i>Clinical Rheumatology</i> , 2021, 40, 4117-4126.	2.2	2
34	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 101-106.	0.8	1
35	Carotid Intima-media Thickness/Diameter Ratio and Peak Systolic Velocity as Risk Factors for Neurological Severe Ischemic Events in Takayasu Arteritis. <i>Journal of Rheumatology</i> , 2022, 49, 482-488.	2.0	1
36	Potential risk of hyperuricemia: leading cardiomyocyte hypertrophy by inducing autophagy. <i>American Journal of Translational Research (discontinued)</i> , 2020, 12, 1894-1903.	0.0	0

#	ARTICLE	IF	CITATIONS
37	The value of ultrasonography combined with clinical features for predicting carotid imaging progression of Takayasu's arteritis: a prospective cohort study. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 101-106.	0.8	0
38	Curcumin alleviates inflammation in Takayasu's arteritis by blocking CCL2 overexpression in adventitial fibroblasts. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 129, 161-170.	0.8	0